Inhibition of Y1 receptor signaling improves islet transplant outcome by Loh, Kim et al.
                                                                    
University of Dundee
Inhibition of Y1 receptor signaling improves islet transplant outcome
Loh, Kim; Shi, Yan Chuan; Walters, Stacey; Bensellam, Mohammed; Lee, Kailun; Dezaki,
Katsuya
Published in:
Nature Communications
DOI:
10.1038/s41467-017-00624-2
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Loh, K., Shi, Y. C., Walters, S., Bensellam, M., Lee, K., Dezaki, K., ... Herzog, H. (2017). Inhibition of Y1
receptor signaling improves islet transplant outcome. Nature Communications, 8(1), [490].
https://doi.org/10.1038/s41467-017-00624-2
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 11. Mar. 2020
ARTICLE
Inhibition of Y1 receptor signaling improves islet
transplant outcome
Kim Loh1,2, Yan-Chuan Shi1,3, Stacey Walters4, Mohammed Bensellam5,7, Kailun Lee1, Katsuya Dezaki6,
Masanori Nakata6, Chi Kin Ip1, Jeng Yie Chan5, Esteban N. Gurzov 2, Helen E. Thomas2, Michaela Waibel2,
James Cantley5,8, Thomas W. Kay2, Toshihiko Yada6, D. Ross Laybutt5, Shane T. Grey4 & Herbert Herzog1,3
Failure to secrete sufﬁcient quantities of insulin is a pathological feature of type-1 and type-2
diabetes, and also reduces the success of islet cell transplantation. Here we demonstrate
that Y1 receptor signaling inhibits insulin release in β-cells, and show that this can be
pharmacologically exploited to boost insulin secretion. Transplanting islets with Y1 receptor
deﬁciency accelerates the normalization of hyperglycemia in chemically induced diabetic
recipient mice, which can also be achieved by short-term pharmacological blockade of Y1
receptors in transplanted mouse and human islets. Furthermore, treatment of non-obese
diabetic mice with a Y1 receptor antagonist delays the onset of diabetes. Mechanistically, Y1
receptor signaling inhibits the production of cAMP in islets, which via CREB mediated
pathways results in the down-regulation of several key enzymes in glycolysis and ATP
production. Thus, manipulating Y1 receptor signaling in β-cells offers a unique therapeutic
opportunity for correcting insulin deﬁciency as it occurs in the pathological state of type-1
diabetes as well as during islet transplantation.
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Insulin is the key hormone that regulates glucose metabolismand its release from β-cells is tightly controlled by homeostaticmechanisms1. Dysregulated release of insulin in response to
changes in physiological glucose is central to the pathophysiology
of type-1 (T1D) and type-2 (T2D) diabetes2–4, thus efforts to
increase insulin secretion in response to physiological demands
represents a signiﬁcant area of interest. Currently, islet trans-
plantation is being explored as a potential treatment option for
T1D patients to become insulin independent5. However, the
efﬁciency of this approach remains poor due to the low survival
rate and diminished efﬁciency of donor islets6 further aggravated
by the scarcity of donor organs. Therefore, it is recognized that
any improvement in this therapeutic option will require a
methodology that enhances β-cell function and survival during
transplantation. Efforts to achieve this have been mainly directed
at the pathways that stimulate insulin secretion, however, with
limited success. Although much is known about what inhibits
insulin secretion, improving β-cell function by targeting the
pathways that suppress the release of insulin remain largely
unexplored as a therapeutic option.
Interestingly, it has been demonstrated that upregulation
of intracellular cyclic adenosine monophosphate (cAMP) can
promote insulin release and improve pancreatic β-cell function7–11.
For instance, increasing cAMP levels, as a result of glucagon-like-
peptide 1 (GLP-1) signaling in β-cells potentiates insulin
secretion12, highlighting this pathway as a critical control point.
Importantly, Y-receptors (Y1, Y2, Y4, Y5, and y6)13, 14 which are
activated by neuropeptide Y (NPY) family members preferentially
associate with Gi/o G-proteins and, therefore, act in an inhibitory
fashion reducing cAMP levels15–17. Particularly, Y1 receptors are
highly expressed in β-cells, indicating the potential for an inhibitory
effect of Y1 receptor signaling to directly regulate insulin release
from β-cells.
Moreover, the other Y-receptor ligands, peptide YY (PYY) and
pancreatic polypeptide, are found to be expressed in L-type cells
of the gut as well as various pancreatic cell types18, 19. PYY
released in the gut in response to food ingestion is well recognized
for its role to inhibit feeding and increase energy expenditure
through the activation of hypothalamic and brain stem
Y-receptors20–23. Importantly, PYY has also been implicated in
the inhibition of insulin release and this notion was supported by
studies showing that application of PYY decreases glucose-
stimulated insulin secretion from rat and mouse islets21, 24, 25.
Although these results suggest that PYY may act through a
paracrine mechanism to tonically inhibit insulin secretion in the
islets, the precise Y receptor mediating this is unclear. Here, we
demonstrate that PYY suppressed insulin secretion via Y1
receptor and inhibition of Y1 receptor signaling in islets
is advantageous for the enhancement of β-cell function. Our
ﬁndings have direct relevance to the clinical scenario of islet
transplantation and could potentially serve as a new therapeutic
option to enhance the efﬁciency and efﬁcacy of islets derived from
deceased organ donors, but also alternate sources including
xenogeneic or stem-cell-derived islets.
Results
Y1 receptor signaling in β-cells controls insulin secretion. In
addition to L-type cells, PYY is also expressed in α-cells of mouse
and human pancreatic islets26, 27 (Fig. 1a), allowing for a possible
paracrine action of PYY signaling via Y1 receptors expressed on
β-cells to inhibit cAMP production, thereby reducing insulin
release. Previous research has shown that genetic deletion of PYY
or Y1 receptor genes in mice leads to a phenotype with increased
serum insulin levels21, 28. Consistent with these ﬁndings the
overproduction of PYY in transgenic mice results in the opposite
phenotype, with reduced serum insulin levels29. Using a β-cell
speciﬁc ‘translating ribosome afﬁnity puriﬁcation’ mouse model
we could show speciﬁc enrichment of Y1 receptor mRNA in
β-cells conﬁrming the physical localization of this Y-receptor
speciﬁcally in β-cells (Supplementary Fig. 1a). To verify the purity
of this preparation we also performed quantitative reverse
transcription PCR (qRT-PCR) on other β-cell speciﬁc genes
including Ins1, Mafa1, Pdx1, Nkx6.1 and as a negative control Pyy
all showing the expected enrichment or absence, respectively
(Supplementary Fig. 1b). To further investigate whether Y1
receptors in β-cells are under a regulatory control depending on
energy status, we determined Y1 receptor expression in the β-cells
from lean and 12-week high-fat diet fed obese mice. Interestingly,
we found that Y1 receptor expression was signiﬁcantly
downregulated in obese hyperinsulinemic mice (Fig. 1b) indica-
ting that reduced Y1 receptor signaling may be required for
β-cells to secrete more insulin as a compensatory mechanism
speciﬁcally under conditions of an insulin resistance state. This is
consistent with the observed increase in insulin levels in β-cell
speciﬁc Y1 knockout mice fed a high-fat diet (Supplementary
Fig. 2a). To further functionally test this we performed glucose-
stimulated insulin release (GSIS) experiments on isolated islets of
C57BL/6JAusb (wild type, WT) and β-cell speciﬁc Y1 knockout
mice. As shown in Fig. 1c, PYY signiﬁcantly reduced insulin
release from cultured islets stimulated with 11 mM glucose.
Importantly, addition of the selective Y1 receptor antagonist
BIBO330430 completely abolished PYY-induced inhibition of
insulin release (Fig. 1c). Consistent with this, lack of Y1 receptors
in β-cells renders them more responsive to glucose with sig-
niﬁcantly elevated insulin levels already observed with stimula-
tion of 2 mM glucose (Supplementary Fig. 2b). To assess the
dynamics of glucose-stimulated insulin secretion in response to
PYY and Y1 receptor antagonism on islets we performed islet
perifusion studies in WT islets. As shown in Fig. 1d, e, PYY
signiﬁcantly inhibits the ﬁrst phase response of glucose-
stimulated insulin secretion whereas Y1 antagonism employing
BIBO3304 treatment resulted in enhanced insulin secretion
primarily by increasing the second phase of the insulin secretory
response (i.e. 40 min time point). Together, these data demon-
strate the critical role of Y1 receptor signaling as a negative
regulator of insulin release in pancreatic β-cells under a physio-
logical glucose load.
Enhanced islet transplantation efﬁciency employing Y1
deﬁcienct islets. We next conducted a series of studies exploring
the potential beneﬁcial clinical effects of enhancing insulin
secretion in situations of limited β-cell mass, through manip-
ulation of the Y1 receptor system. We performed islet trans-
plantation experiments and speciﬁcally investigated whether Y1
receptor-deﬁcient islets could provide better metabolic control
when compared to control WT islets. For this, alloxan-induced
diabetic C57BL/6JAusb mice were transplanted with either a
minimal amount of 60 islets originating either from WT or Y1−/−
mice, respectively, or as a control for islet quality, with a sufﬁcient
(optimal) mass of 300 WT islets. Islets of comparable size were
hand-picked and as shown in Supplementary Fig. 2c β-cell mass
was not signiﬁcantly different between Y1−/− or WT mice,
therefore material with equal insulin content was transplanted.
Blood glucose levels were then monitored for the next 20 days. As
expected, mice receiving the optimal islet mass showed immediate
restoration of blood glucose control (Fig. 1f), whereas mice
receiving a minimal number of WT islets had only a slight trend
to improved blood glucose control by day 15 post-transplanta-
tion, which never completely normalized (Fig. 1f, g). In marked
contrast, mice transplanted with the minimal number of 60 Y1−/−
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islets showed signiﬁcant glycemic improvement by day 5 post-
transplantation and by day 7 blood glucose levels were compar-
able with the mice receiving the optimal islet mass transplant
(Fig. 1f). Consistent with the improved glycemic control, glucose
tolerance at day 5 post-transplantation was also signiﬁcantly
improved in mice that received the Y1−/− islets (Fig. 1h, i), which
was due to the improved in vivo insulin secretory response of the
Y1−/− islets (Fig. 1j, k). Improved in vivo insulin secretion was
also highlighted by the superior insulin disposition index (DIo) of
mice receiving Y1−/− islets; being 2.58 fold higher compared to
mice receiving WT islets (DIo= 0.021± 0.0017 vs. 0.054± 0.019
for Y1−/− vs. WT, respectively; n= 4 mice per group). Together,
these data demonstrate that reduced Y1 receptor signaling in
islets is advantageous for the enhancement of insulin release, and
this can have direct relevance to the clinical scenario of islet
transplantation where donor islets are of limited supply.
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Inhibition of Y1 receptor signaling improves islet transplantat
outcomes. To prove whether these beneﬁcial effects of lack of Y1
receptor signaling could also be induced pharmacologically, we
ﬁrst examined the impact of BIBO3304, a selective non-brain
penetrable Y1 receptor antagonist, on glucose induced insulin
secretion in vivo. C57BL/6JAusb mice were treated 2 h prior to a
bolus glucose load orally with 0.5 μM BIBO3304, a dose known
to have physiological action31, and serum insulin levels were
assessed over the next 60 min. Mice that received BIBO3304
exhibited signiﬁcantly increased serum insulin levels (Fig. 1l, m)
conﬁrming that blocking Y1 receptor signaling is able to enhance
physiologically triggered insulin secretion. To further test whether
this pharmacological intervention could improve the outcome of
islet transplantation, we repeated the transplantation experiments
using a minimal number of WT islets, and then treated half of the
mouse cohort orally with BIBO3304 and the other half with
placebo. As a control for islet quality, a group of mice were
transplanted with an optimal islet mass. Recipient mice that were
treated with placebo failed to achieve normoglycemia and
remained diabetic throughout the course of the experiment
(Fig. 2a, b). In contrast, mice transplanted with the minimal
amount of WT islets and treated with BIBO3304 rapidly achieved
normoglycemia (Fig. 2a). Strikingly, when antagonist treatment
was stopped at day 10 post-transplantation these mice were able
to maintain normoglycemia till the end of the experiment at day
60 (Fig. 2a). This suggests that transient inhibition of Y1 receptor
signaling in the early period after islet transplantation is sufﬁcient
to normalize glucose homeostasis. Consistent with the improved
glycemic control, glucose tolerance at day 5 post-transplantation
was also signiﬁcantly improved in the BIBO3304-treated group
compared to the placebo group (Fig. 2c, d). Consistently,
BIBO3304-treated mice also showed a superior DIo being 12.28-
fold higher than placebo-treated mice (DIo= 0.066± 0.0082 vs.
0.819± 0.324 for placebo vs. BIBO3304, respectively; n= 4 mice
per group). Analysis of BIBO3304-treated compared to untreated
islet grafts did not reveal any obvious differences in islet
morphology, apoptosis, graft vascularization, or endoplasmic
reticulum (ER) stress response (Supplementary Figs. 3, 4a),
however, the number of Ki67-positive β-cells in the BIBO3304-
treated grafts was signiﬁcantly increased (Fig. 2e, f). Together,
these data demonstrate that the improved glycemic control in
BIBO3304-treated mice was a consequence of increased insulin
secretion and islet proliferative capacity in response to changes in
physiological glucose levels (Fig. 2e–h).
In order to test the time dependence of Y1 receptor antagonism
on islet transplantation outcomes, mice were transplanted with a
minimal islet mass and half of the cohort were treated daily with
BIBO3304 from day 1 and the other half of the cohort were
treated with placebo. After 8 days the placebo-treated group also
received BIBO3304 treatment. As seen before, mice that initially
received placebo treatment were not able to achieve normal
glucose levels (Fig. 2i): however, when switched over to BIBO3304
treatment at day 9, these mice showed a signiﬁcant improvement
in glycemic control (Fig. 2i), which was evident within the ﬁrst few
days post BIBO3304 treatment and by day 18 these mice achieved
comparable glycemic control to mice that had been fed BIBO3304
from day 1 (Fig. 2i). Signiﬁcantly, the improvement in glycemic
control was maintained even after the subsequent discontinuation
of BIBO3304 treatment at day 20 (Fig. 2i). To demonstrate that
glycemic control was dependent on the islet grafts a cohort of
these mice underwent survival nephrectomy at day 60, resulting in
all mice having rapid reversal of glycemic control and a return to
hyperglycemia (Fig. 2j). These data indicate that even delayed
short-term Y1 receptor intervention can restore normoglycemia in
previously non-functioning islet grafts. To test the long-term
stability of the BIBO3304 effect upon islet graft function, an
additional cohort of mice were transplanted with a minimal islet
mass and treated with BIBO3304 for the ﬁrst 10 days post
transplant at which time treatment was discontinued. These mice
exhibited stable normoglycemia for > 260 days. After survival
nephrectomy all mice rapidly lost glycemic control and returned
to hypergylcemia (Fig. 2k) demonstrating that short-term
BIBO3304 treatment can provide stable, long-term improvement
in islet graft function.
Y1 antagonism enhances human islet function and transplan-
tat outcomes. We next investigated the physiological relevance of
Y1 receptor signaling on insulin secretion in human islets. To
investigate whether and which Y-receptors are present in human
islets, we performed micro-array analysis and conﬁrmed that
consistent with mouse β-cells, the Y1 receptor is the only Y-
receptor expressed at signiﬁcant levels by human
islets (Supplementary Table 1). In order to test the physiological
relevance of Y1 receptor signaling in human islets, human islets
were cultured and stimulated with glucose in the presence or
absence of the Y1 receptor antagonist BIBO3304. Similar to rodent
islets, human islets treated with BIBO3304 exhibited enhanced
insulin secretion in response to a glucose challenge (Fig. 3a).
We next determined whether pharmacological inhibition of
Y1 receptor signaling with BIBO3304 would improve human
islet function in vivo after islet transplantation. For this, human
islets were transplanted into diabetic NOD RAG1−/− mice that
were subsequently treated with BIBO3304 or placebo after trans-
plant and their blood glucose levels were monitored. Placebo-
treated mice did not show a return to normoglycaemic levels
(i.e., < 10mM glucose) over the monitoring period of 15 days
(Fig. 3b, c). In contrast, mice treated with BIBO3304 sho-
wed signiﬁcantly accelerated recovery of glucose control, reaching
normal glucose levels by day 5. Consistent with the improved
glycemic control, glucose tolerance was also signiﬁcantly improved
in the BIBO3304-treated group compared to the placebo group
Fig. 1 Improved glycemic control in diabetic mice transplanted with Y1 receptor-deﬁcient islets. a Photomicrograph showing immune ﬂuorescence staining
for insulin (green), PYY (red) and DAPI (blue) in islets from human, wild type, and PYY knockout mice. Scale bar, 25 μm. b Y1 receptor mRNA expression in
pancreatic islets isolated from lean or obese mice determined by qRT-PCR (n= 4). c Pancreatic islets from C57BL/6JAusb mice were isolated and cultured.
Insulin secretion was determined in response to 2 and 11 mM glucose in the presence of PYY and/or Y1 receptor antagonist BIBO3304 (n= 3). d Perifusion
experiment to record insulin release over a 50min period using islets from C57BL/6JAusb mice stimulated with 11 mM glucose and treated with PYY or Y1
antagonist BIBO3304. (n= 4–5). e Results expressed as area under the curve. f Alloxan-induced diabetic mice were transplanted with an optimal number
(300) of WT islets (n= 8) or a minimal number (60) fromWT islets (n= 15) or Y1−/− islets (n= 13) and blood glucose levels were monitored for 20 days.
g Results expressed as area under the curve. h–k Diabetic mice receiving 60 WT (n= 4) or Y1−/− (n= 4) islets were fasted overnight and i.v. glucose
tolerance tests (1 g/kg body weight) were performed at day 5 post-transplant. Blood glucose levels and insulin production during glucose tolerance tests
were monitored. Results are expressed over the time course and as area under the curve. l, m 7-week-old C57BL/6JAusb mice were treated with placebo
(n= 6) or with 0.5 μM of the Y1 receptor speciﬁc antagonist BIBO3304 (n= 6), 2 h prior to i.p. glucose injection (1 g/kg body weight) and serum insulin
levels in response to glucose administration at indicated time points were determined. Results are also expressed as area under the curve. Data are shown
as mean± s.e.m. *P< 0.05, **P< 0.01, calculated by t-test (b, c) or two-way ANOVA analysis
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(Fig. 3d, e). This improved glycemic control in BIBO3304-treated
mice was accompanied by increasedcirculating human insulin
levels (Fig. 3f). Together these data demonstrate that the action of
Y1 receptor signaling to modulate insulin secretion is conserved in
human islet physiology.
To assess Y1 receptor antagonism as a potential treatment
option in islet transplant patients a model that more closely
mimics the human situation was chosen. For this, islets were
transplanted across a full MHC mismatch (BALB/c islet −>
C57BL/6 diabetic recipient) to mimic the situation of human islet
transplantation with immune-mediated allogeneic rejection.
Under this setting, the transplantation of the optimal 300 islets
restored metabolic control whereas the minimal mass of 60 islets
in mice treated with placebo did not (Fig. 3g). Importantly, the
administration of Y1 receptor antagonist rescued the function of
the limiting islet mass such that mice receiving 60 islets and
treated with BIBO3304 show complete restoration of full
metabolic function equivalent to mice that received 300 islets
(Fig. 3g). These experiments demonstrate that Y1 receptor
antagonism is able to rescue islet function even in the context
of ongoing immune-mediated allograft rejection. Of note, the
time to rejection for mice receiving 60 islets plus Y1 receptor
antagonist or 300 islets was the same, suggesting BIBO3304 was
not impacting on the immune response but rather enhancing islet
function, consistent with our earlier results.
Y1 antagonism improves glycemic control and delays the onset
of type 1 diabetes. Due to the success of BIBO3304 in controlling
blood glucose in mice transplanted with a minimal number of
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Fig. 3 Improved human islet transplant outcomes due to Y1 receptor antagonism. a Human islets from three independent donors were isolated and cultured
for 48 h. Insulin secretion from human islets was determined in response to 2.8 and 28mM glucose with or without 1 μM BIBO3304 (n= 3; triplicate; three
independent donors). b, c Alloxan-induced NOD RAG1−/− diabetic mice were transplanted with human islets (IEQ 1400) and subsequently orally treated
with or without 0.5 μM BIBO3304 and blood glucose levels were monitored for 15 days after which survival nephrectomy was performed
(n= 7 per group; two independent donors). Results are also expressed as area under the curve. d, e Human islet recipient mice treated with placebo or
0.5 μM BIBO3304 for 7 days (n= 4) were fasted for 6 h and i.p. glucose tolerance tests (1 g/kg body weight) were performed. Results were also expressed
as area under the curve. f Serum insulin levels in human islet recipient mice were determined at day 15 post-transplantation (n= 7). g Alloxan-induced
diabetic mice were transplanted with a full MHC mismatch (BALB/c islet −>C57BL/6) optimal number of allogeneic islets (300) (n= 6) or 60 allogeneic
islets (n= 14) and treated daily with either 0.5 μM BIBO3304 (n= 6) or placebo (n= 8). h 6-week-old female NOD mice were treated with placebo or
0.5 μM BIBO3304 daily and glucose levels monitored weekly (n= 16 per group). iWhen the blood glucose levels in BIBO3304-treated mice eventually also
reached 12mM, a 10-fold higher dose of BIBO3304 was given in an attempt to reverse the hyperglycemia (n= 3). j, k, l Glucose tolerance tests were
performed in BIBO3304-treated and placebo-treated NOD mice at 11, 15, and 19 weeks of age, respectively (n= 6 per group). m Results were also
expressed as area under the curve. n, o Insulitis was scored on islets from NOD mice either treated with 0.5 μM BIBO3304 or placebo at 12 or 22 weeks of
age (n= 6, n= 5), respectively. Data are means± s.e.m. *P< 0.05, **P< 0.01; ***P< 0.001 calculated by t-test (a, c, e, f) or two-way ANOVA analysis
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mouse or human islets, we considered whether this would also be
effective in other settings with reduced insulin secretory capacity.
We therefore next determined whether Y1 receptor antagonism
could extend the period of normoglycemia in autoimmune prone
non-obese diabetic (NOD) mice. Abnormalities of β-cell function
can be detected in NOD mice before they develop diabetes32 and
this is also true in humans who have dysglycemia before they
develop T1D33. Similarly, following diagnosis of T1D there is a
period with reduced β-cell function that sometimes is still sufﬁ-
ciently effective for insulin treatment to be ceased for a period of
time is called the ‘honeymoon period’. We tested if BIBO3304
would improve glycemic control in NOD mice prior to diabetes
with potential application to reducing dysglycemia before and
after diagnosis of diabetes and possibly prolonging
the time to diagnosis of T1D and duration of the honeymoon
period.
WT
Y1–/–
0.0
0.5
1.0
1.5
2.0
2.5
m
R
N
A 
le
ve
ls
 (fo
ld)
** *
*
*
* *
0
1
2
3
4
m
R
N
A 
le
ve
ls
 (fo
ld) *
**
*
0.0
0.1
0.2
0.3
0.4
Pa
nc
re
as
 w
ei
gh
ts
 (g
)
a
e
c
Pl
ac
eb
o
BI
BO
 3
30
4
f
W
T
Y1
–
/–
Insulin
l
pCREB
α-Tubulin
WT Y1–/–
d
BIBO 3304
Placebo
0
50
100
150
200
Is
le
t n
um
be
r
BIBO 3304
Placebo
0
200,000
400,000
600,000
800,000
*
BIBO 3304
Placebo
0.0
0.2
0.4
0.6
0.8
1.0
*
BIBO 3304
Placebo 2 mM G
20 mM G
20 mM G+Exanetide
20 mM G+Exanetide+PYY
20 mM G+Exanetide+PYY+BIBO3304
WT
Y1–/–
m
0
10
20
30
40
cA
M
P 
le
ve
l
(pm
ol/
mg
 pr
ote
in)
0
10
20
30
40
cA
M
P 
le
ve
l
(pm
ol/
mg
 pr
ote
in)
** * ** *
WT WT WT WT WT
0
1
2
3
pC
RE
B/
tu
bu
lin
 (fo
ld) *
0
1
2
3
pC
RE
B/
tu
bu
lin
 (fo
ld)
*
pCREB
α-Tubulin
Placebo BIBO 3304
Pl
ac
eb
o
BI
BO
 3
30
4
BIBO 3304
Placebo
BIBO 3304
Placebo
*
WT Y1–/–Y1–/–Y1–/–Y1–/–Y1–/–
p=0.06
*
43 kDa
50 kDa
50 kDa
pCREB DAPI Overlay Insulin pCREB DAPI Overlay
20 μm20 μm
Glucokinase Mdh2 HadhTpi1 Pyruvate
carboxylase
ATP citrate
lyase
Glucokinase Mdh2 HadhTpi1 Pyruvate
carboxylase
ATP citrate
lyase
%
 o
f K
i6
7
po
sit
ive
 β-
ce
lls
 
Is
le
t a
re
a 
(μm
2 )
b
h i
g
j k
50 μm
Insulin/DAPIInsulin/DAPI
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00624-2 ARTICLE
NATURE COMMUNICATIONS |8:  490 |DOI: 10.1038/s41467-017-00624-2 |www.nature.com/naturecommunications 7
In order to test the responsiveness of NOD mice to Y1 receptor
antagonism we treated 7-week-old NOD mice with a single dose
of 0.5 μM BIBO3304 for 1 h before the onset of the dark phase
(1900 hours) and measured glucose levels at 0900 hours the
following day. Interestingly, NOD mice treated with BIBO3304
displayed a signiﬁcant decrease in glucose levels (Placebo, 5.35±
0.11 mM; BIBO3304, 5.03± 0.09 mM; *P< 0.05), which is
associated with a strong trend to increased insulin levels (Placebo,
73.31± 9.42 pM; BIBO3304, 103.2± 11.87 pM; P= 0.06), indi-
cating that β-cells in a T1D environment are responsive to the
inhibition of Y1 receptor signaling. To determine whether
BIBO3304 treatment would prevent or delay the onset of diabetes
in NOD mice, we treated a cohort of NOD mice daily with either
BIBO3304 or placebo from 6 weeks of age onwards. As expected
placebo-treated NOD mice exhibited worsening glucose control
over time and eventually developed overt diabetes (Fig. 3h). In
contrast, BIBO3304-treated NOD mice showed a marked
resistance to the onset of hyperglycemia for an extended period
(2–4 weeks) (Fig. 3h), but eventually these mice treated with 0.5
μM BIBO3304 also progressed to hyperglycemia (Fig. 3i).
However, when these BIBO3304-treated NOD mice were
diagnosed with hyperglycemia (glucose levels >12 mM), increas-
ing the BIBO3304 dose 10-fold was able to reverse this trend and
further delay the onset of overt hyperglycemia (Fig. 3i).
Consistent with the concept that BIBO3304 treatment improves
β-cell function, NOD mice treated with BIBO3304 showed
signiﬁcantly better glucose tolerance over the time course of
BIBO3304 treatment at 15 and 19 weeks of age, respectively
(Fig. 3j–m). In comparison, placebo-treated NOD mice showed a
worsening glucose tolerance consistent with their progression to
overt hyperglycemia and diabetes (Fig. 3j–m). The improvement
in glycemic control provided by BIBO3304 at least in the early
phase (12 weeks of age) was independent of effects on the
immune system as there were no differences in T-cell and B-cell
populations in placebo vs. BIBO3304-treated mice. In particular
there was no evidence of a change in the speed of an autoimmune
attack as there was no difference in critical immune markers
associated with autoimmune diabetes in the spleen, pancreatic
lymph nodes, and mesenteric lymph nodes (Supplementary
Fig. 5). Furthermore, BIBO3304 treatment had no signiﬁcant
effect on the expression levels of classical ER stress-mediating
gene-products in islets from NOD mice excluding this pathway as
a likely reason for the observed improved islet function
(Supplementary Fig. 6a). Investigating the degree of immune
destruction in these NOD mice, insulitis scores revealed that
overall there was no signiﬁcant difference between placebo or
BIBO3304-treated animals at 12 weeks of age (Fig. 3n) and again
further into disease progression at 22 weeks of age (Fig. 3o), or
β-cell area (Supplementary Fig. 6b). This data suggests that
improving insulin secretion due to Y1 receptor antagonism is the
main driver of the prolonged control of glucose homeostasis in
the NOD mice. Together, these results suggest Y1 receptor
antagonism may be beneﬁcial clinically to prolong the honey-
moon period in new-onset T1D patients by enhancing insulin
secretion.
To investigate the general effects chronic antagonism of Y1
receptor signaling has on islets, we treated a set of 7-week-old WT
mice with BIBO3304 or placebo for 7 weeks, upon which animals
were sacriﬁced, pancreata isolated, and analyzed. While showing
a slight trend, there was no signiﬁcant increase in pancreas weight
in the BIBO3304-treated mice (Fig. 4a) nor any difference in total
islet numbers (Fig. 4b). Interestingly, however, islets from
BIBO3304-treated mice appeared to be larger in size (Fig. 4c)
and total islet area due to an increase of individual islet size was
signiﬁcantly greater in the BIBO3304-treated mice compared to
the placebo group (Fig. 4d). This increased islet size was most
likely due to increased β-cell proliferation consistent with the
increased number of Ki67-positive cells seen in the BIBO3304
group (Fig. 4e). Taken together, this suggests that Y1 receptor
antagonism in the β-cells may not only promote insulin secretion
but also enhance β-cell proliferation.
Y1 receptor signaling regulates β-cell function via a cAMP
dependent pathway. In order to gain mechanistic insight on the
consequences of Y1 receptor signaling in islet cells we performed
a series of in vitro experiments. Since the Y1 receptor interacts
with Gi/o G-proteins, which act to inhibit adenylate cyclase
activity and cAMP levels modulate insulin secretion, we investi-
gated cAMP production in control and Y1−/− islets in response to
glucose. For this we tested whether pharmacologically blocking
Y1 receptor signaling in islets can reproduce this effect ex vivo.
To mimic physiological conditions we treated islets isolated from
WT mice with the GLP-1 receptor agonist ‘Exenatide’ in the
presence of glucose to raise cAMP levels. As shown in Fig. 4f,
cAMP was signiﬁcantly upregulated in the presence of 100 nM
Exenatide and 20 mM glucose compared to glucose alone.
The addition of 50 nM PYY was able to signiﬁcantly reduce
the Exenatide-induced increase in cAMP and this inhibitory
effect was abolished in the presence of the Y1 receptor
speciﬁc antagonist BIBO3304 (Fig. 4f). To investigate whether the
GLP-1-induced increase in cAMP could be further enhanced in
the absence of Y1 receptor signaling, we also performed the
experiment on islets derived from Y1−/− mice. The addition of
Exenatide resulted in a further increase in cAMP levels in Y1−/−
islets pretreated with 20 mM glucose (Fig. 4g). Importantly, the
addition of PYY or PYY and BIBO3304 had no signiﬁcant effect
on reducing cAMP levels in the Y1−/− islets consistent with a Y1
receptor-dependent effect.
Taken together, these data demonstrate that Y1 receptor
signaling can counteract the Exenatide-induced enhancement
of insulin secretion via direct effects on cAMP production.
Fig. 4 Y1 receptor signaling regulates β-cell function via a cAMP-CREB-dependent pathway. a Pancreas weight of BIBO3304 vs. placebo-treated WT mice
(n= 3). b Total islet number of BIBO3304 compared to placebo-treated WT mice (n= 3). c Representative photomicrographs of islets stained for insulin
from BIBO3304 and placebo-treated WT mice (n= 3). d Total islet area of BIBO3304 compared to placebo-treated WT mice (n= 3). e Quantiﬁcation
of Ki67-positive β-cells in islets from BIBO3304 or placebo-treated WT mice. f cAMP production of WT islets in response to 2 and 20mM glucose
co-stimulation with GLP-1 receptor agonist, Exenatide (100 nM), in the presence or absence of PYY (50 nM), or BIBO3304 (1 μM) (n= 5). g cAMP
production of Y1−/− islets in response to 2 and 20mM glucose co-stimulation with GLP-1 receptor agonist, Exenatide (100 nM), in the presence or absence
of PYY (50 nM), or BIBO3304 (1 μM) (n= 5). h, i Pancreatic islets from WT mice treated with placebo or BIBO3304 and Y1−/− mice were isolated and
subjected to SDS–PAGE and western blot analysis using anti-p-CREB and α-tubulin antibodies (n= 5–7). j, k Representative ﬂuorescence micrographs of
pancreata from WT mice treated with placebo or BIBO3304 and Y1−/− mice showing staining for insulin (red), phospho-CREB (green) and nuclear
counterstained with DAPI (blue), scale bar= 20 μm. l, m Pancreatic islets from Y1−/− and WT mice treated with placebo or BIBO3304 were isolated and
genes involved in insulin secretory pathways including glucokinase, Tpi1, pyruvate carboxylase, Mdh2, ATP citrate Lyase, and Hadh were determined using
quantitative RT-PCR. Cyclophillin A and Rpl19 were used as a housekeeping gene (n= 3). Data are means± s.e.m. *P< 0.05, **P< 0.01, calculated by t-test
(c, e, f) or two-way ANOVA analysis
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Further support for this concept comes from studies where we
could show that protein levels of phosphorylated cAMP
responsive element-binding protein (pCREB) are signiﬁcantly
upregulated in islets of Y1−/− or BIBO3304-treated WT mice as
determined by western blotting (Fig. 4h, i) and in situ immuno-
ﬂuorescence (Fig. 4j, k).
Since CREB expression may also be inﬂuenced by Ca2+ and
Ca2+ is a vital part of the exocytosis of insulin containing
secretory granules, we performed [Ca2+]i measurements to
investigate whether Y1 receptor signaling is critical for these
events. A repetitive stimulation with 11 mM glucose induced
repeated [Ca2+]i increases in mouse single β-cells as expected and
PYY (10 nM), added to the superfusion solution 5 min prior to
the second glucose stimulation, did not affect [Ca2+]i responses to
11 mM glucose (Supplementary Fig. 7a). The ratio of the peak
amplitude of the [Ca2+]i response to the second glucose
stimulation (S2) compared to that of the ﬁrst stimulation (S1),
and the S2/S1 ratio was also unaltered by PYY (Supplementary
Fig. 7b). Furthermore, PYY did not affect the oscillation of
[Ca2+]i during the second phase response to 11 mM
glucose (Supplementary Fig. 7c) nor did it inﬂuence the KCl
(25 mM)-induced [Ca2+]i increases at 2 mM glucose in β-cells
(Supplementary Fig. 7d, e). As such, Ca2+ does not seem to play a
major role in PYY/Y1 receptor mediated downstream processes
in β-cells suggesting that Y1 receptor signaling primarily inhibits
the CREB-dependent pathway to inﬂuence insulin secretion.
We next investigated whether key cellular molecules known to
be involved in the insulin secretion process are under the control
of the CREB transcription factor. The expression of several genes
involved in glycolysis such as the rate-limiting enzyme glucoki-
nase34, the anaplerotic enzyme pyruvate carboxylase (Pc)35 and
in mitochondrial oxidation process, malate dehydrogenase
(Mdh2)36, ATP citrate lyase and 3-hydroxyacyl-CoA dehydro-
genase (Hadh)37 are known to respond to CREB. Consistent with
this, quantitative real-time PCR (qPCR) performed on RNA
isolated from Y1−/− islets conﬁrmed an increase in mRNA
expression of these critical metabolic genes in the absence of Y1
receptor signaling (Fig. 4l). Absence of Y1 receptor signaling also
increased the expression of CREB downstream target genes
controlling mitochondrial oxidation including Mdh2, ATP citrate
lyase, and Hadh (Fig. 4l). Consistent with this notion that
Y1 receptor signaling via the cAMP/CREB pathway controls
insulin secretion, repeating this analysis in WT islets that were
treated with BIBO3304 revealed that while not all the genes
investigated were upregulated a similar pattern of altered gene
expression of glycolysis controlling genes was observed (Fig. 4m).
It is not too surprising that the effects of Y1 receptor deletion,
which occurred in the germline, may result in a more extended
change in expression of β-cell speciﬁc genes than what could be
expected from a short-term treatment regime using an antagonist.
Interestingly, however, the effect that BIBO3304 has on the
expression of the set of glycolysis controlling genes that are
increased seems to be more pronounced and almost double
suggesting modulating this set of genes is sufﬁcient to produce the
increase in insulin secretion.
In contrast to changes in these key metabolic genes, genes that
inﬂuence the maintenance of the β-cell phenotype were not
signiﬁcantly altered (Supplementary Fig. 8a–c). Entry of glucose
into the β-cell with subsequent glycolysis and mitochondrial
oxidation is a critical trigger for the release of appropriate
amounts of insulin in response to changes in physiological
glucose. However, expression levels of Glut2, the key transporter
governing glucose uptake into the β-cell and subsequent entry
into glycolysis was not signiﬁcantly changed in the β-cells of
Y1−/− mice (Supplementary Fig. 8d), again suggesting that Y1
receptor signaling predominantly regulates cAMP levels and
CREB activity, which via upregulation of enzymes that are central
in controlling glycolysis plays a key role in the physiological
control of insulin secretion.
Discussion
By using genetic and pharmacological approaches our results
reveal that Y1 receptors play an essential and conserved role in
β-cell physiology by providing an inhibitory action in modulating
insulin release in response to a glucose load. This ﬁnding
also highlights a potential causal role for impaired Y1 receptor
signaling in the development of metabolic diseases such as
obesity and hyperinsulinemia. Importantly, we demonstrate that
manipulating the Y1 receptor system via pharmacological inter-
vention may be a useful therapeutic approach to boost β-cell
function under conditions where insulin secretion is limited. Our
ﬁndings have the potential for a direct clinical application in the
context of pancreatic islet transplantation, which is emerging as
an important therapy to treat T1D and hypoglycemic unaware-
ness5 but is limited in its scope by the poor function of the
transplanted islets after engraftment and scarcity of donor
material. Indeed, with current best practice most islet transplant
recipients require 2–3 islet transplants to achieve normal
metabolic control with insulin independence38. Based on our
studies here, by employing a Y1 antagonist as co-treatment with
islet transplantation, the required number of islets to achieve the
same level of insulin production could be signiﬁcantly reduced
thereby reducing the number of donors required per recipient
and consequently increasing the number of patients who could
beneﬁt from islet transplantation. In addition to the potential for
improving the current clinical practice of adult islet transplan-
tation, Y1 receptor antagonism may also be applicable to newly
emerging therapies of islet transplantation that take advantage of
alternative islet sources, such as porcine (xenogeneic) or stem
cell-derived (both stem cell and induced pluripotent stem (iPS)
cell) islets. As the effect of Y1 receptor antagonism is highly
effective in the immediate period after transplant and can be
suspended after a short treatment period, targeting the Y1
receptor brings the additional advantage of requiring only a
temporary treatment regime.
Methods
Mice. All animal care and experiments were approved by the Garvan/St. Vincent’s
Animal Ethics Committee. Y1lox/lox mice were generated as previously
described39 and crossed with mice expressing the Cre recombinase gene
under the control of the rat insulin-2 promoter Tg(Ins2-cre)25Mgn/J(INS2cre/+)40
to generate Y1lox/lox/INS2cre/+ mice. INS2cre/+ mice were also crossed onto Gt
(ROSA)26Sortm9(EGFP/Rpl10a)Amc/J mice (JAX stock# 024750) in order to produce
β-cell speciﬁc expression of the EGFP–L10a fusion protein for mRNA isolation
and qPCR analysis. For clarity, islet tissue from these mice is referred to as WT and
Y1−/− respectively, throughout the text. Age-matched and sex-matched mice on a
C57BL/6Ausb background were used for all experiments except stated otherwise.
Female NOD mice were purchased from Australian BioResources Pty Ltd
(ABR, Moss Vale, NSW, Australia). Mice were housed under a controlled tem-
perature of 22 °C and a 12-hour light cycle (lights on from 0700 to 1900 hours)
with ad libitum access to water and a standard chow diet (6% calories from fat, 21%
calories from protein, 71% calories from carbohydrate, 14.0 MJ/kg, Gordon’s
Specialty Feeds, Australia). To avoid the stress caused by gavage, speciﬁc Y1
receptor antagonist BIBO3304 (Tocris Bioscience) was dissolved in distilled water
and administrated daily in a form of jelly for the duration stated in the text. This
method of drug delivery was developed in our lab and described previously31. In
brief, we trained mice to voluntarily eat a vehicle jelly before the start of an
experiment. After 2–5 days training, over 95% of mice consumed the entire portion
of jelly (195 μl for a 25 g mouse) within 1 min of being placed in the cage and
maintained a high avidity for jelly throughout the study period. At the
commencement of an experiment, mice received BIBO3304 containing jelly
once per day for the time period indicated in each study, while control mice
received vehicle jelly.
RNA extraction and quantitative RT-PCR. Pancreatic islets were isolated and
immediately frozen in liquid nitrogen, and RNA was extracted using Trizol
Reagent (Sigma, St. Louis, MO). Isolated mRNA was reverse transcribed into
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cDNA using Superscript III First-Strand Synthesis System (Invitrogen, Australia)
and processed for qPCR with the Light-Cycler 480 Real-Time PCR system
(Roche, Switzerland) for Gk, Tpi1,Acly, Pc, Mdh2, Hadh, Glut2, Pdx1, MafA,
Nkx6.1, NeuroD1 as indicated in the Supplementary Table 2 and normalized with a
housekeeping gene Ribosomal protein L19 (Rpl-19) (5′-CTCGTTGCCGGAAA
AACA-3′ and 5′-TCATCCAGGTCACCTTCTCA-3′). Npy1r (Y1 receptor) gene
(5′-CACAGGCTGTCTTACACG-3′ and 5′-GCGAATGTATATCTTGAAG
TAG-3′). The ampliﬁcation condition used in all the RT-qPCR experiment was:
94 °C for 30 s, 60 °C for 30 s, 72 °C for 20 s for 40 cycles.
Glucose-stimulated insulin secretion ex vivo. Pancreas from 8-week-old to
10-week-old WT and Y1−/− mice were perfused with cold liberase (Roche) solution
via the common bile duct and subsequently pancreata were removed and incubated
at 37 °C for 16 min. The digestion was stopped by addition of Krebs-Ringer
Bicarbonate buffer containing 10% newborn calf serum followed by mechanical
disruption of the pancreas and washing of the islets. Islets were further separated
from other pancreatic tissue using a Ficoll-Paque PLUS (GE Healthcare) density
gradient and hand-picked under a stereomicroscope. Islets were subsequently
incubated in RPMI-1640 medium (containing 10% fetal calf serum, penicillin and
streptomycin, HEPES, 11 mM glucose, and 2 mM glutamine) in a 37 °C, 5% CO2
incubator for 48 h. GSIS assays were performed as previously described41. Brieﬂy,
islets were pre-incubated for 1 h in HEPES-buffered KRB containing 0.1% BSA and
2mM glucose. Experiments were performed in triplicate with batches of ﬁve
islets incubated at 37 °C, 5% CO2 for 1 h in 130 μl KRB containing 0.1% BSA,
supplemented with 2 mM, 11 mM, or 20 mM glucose or 2 mM glucose with KCl
(25 mM) in with or without 100 nM Exenatide (GLP-1 receptor agonist, Byetta)
and/or 50 nM PYY and/or 0.5 μM BIBO3304 as indicated in the text. Insulin
release was determined by insulin RIA kit (Linco Research, St. Charles, MO, USA).
Insulin DIo was calculated from the formula ΔI0−I30/ΔG0−G30 × 1/fasting insulin;
where 1/fasting insulin=serum insulin level determined by ELISA (pM) and
G=blood glucose (mmol/l).
Glucose tolerance tests and in vivo GSIS. Glucose tolerance tests (GTT) were
performed on 6 h-fasted mice that were administered i.p. with glucose (1 g/kg body
weight). Blood glucose levels were assessed at 0, 15, 30, 60, and 90 min after glucose
administration using a Accu-chek Go glucometer (Roche, Dee Why, Australia).
Serum during GTT was collected and stored for subsequent insulin assays using
insulin RIA kits (Linco Research). Fed and fasted serum insulin levels were also
measured using insulin RIA kits (Linco Research). For islet transplantation, mice
were fasted overnight and i.v. administered with glucose (1 g/kg body weight) and
blood glucose levels were assessed at 0, 2, 5, 10, 15, 30, and 60 min after glucose
administration using a glucometer. Blood samples during GTT were collected and
stored for subsequent insulin assays using an ultra-sensitive commercially available
ELISA kit (Crystal Chem, Downers Grove, USA). Human insulin levels during
human islet transplantation were determined using human insulin ELISA kit
(Mercodia AB, Sweden).
cAMP measurement assays. Isolated islets were incubated in RPMI-1640
medium (containing 10% fetal calf serum and penicillin and streptomycin, HEPES,
11 mM glucose, and 2 mM glutamine) in a 37 °C, 5% CO2 incubator for 24 h.
Batches of 40 islets were washed with KRB buffer and subsequently incubated with
KRB buffer containing 0.1% BSA and 2mM glucose at 37 °C, 5% CO2 for 1 h
before the assay. Islets were cultured with 2 mM, 11 mM, or 20 mM glucose,
100 nM Exenatide (Byetta, AstraZeneca) in the presence of 0.5 mM IBMX (Sigma-
Aldrich) and intracellular accumulation of cAMP was measured over a period of 1
h. Islets were lysed in 150 μl 0.1 M HCl for 20 min and cAMP levels were measured
using the ‘Direct cAMP ELISA kit’ (Enzo Life Sciences, Farmingdale, NY)
according to the manufacturer’s protocol. Final cAMP concentrations were nor-
malized by total protein content.
Measurements of [Ca2+]i in single β-cells. Islets isolated from male C57BL/
6Ausb mice were dispersed into single cells in Ca2+-free HKRB. The single cells
were plated sparsely on coverslips and maintained for 1 day at 37 °C, 5% CO2
incubator in Eagle’s minimal essential medium containing 5.6 mM glucose
supplemented with 10% fetal bovine serum, 100 μg/ml streptomycin, and 100 U/ml
penicillin. Dissociated single β-cells on coverslips were mounted in an open
chamber and superfused in HKRB. Cytosolic Ca2+ concentrations ([Ca2+]i) in
single β-cells were measured at 33 °C by dual-wavelength fura-2 microﬂuorometry
with excitation at 340/380 nm and emission at 510 nm using a cooled charge-
coupled device camera. The ratio image was produced on an Aquacosmos system
(Hamamatsu Photonics, Hamamatsu, Japan). Data were taken exclusively from
the cells, which fulﬁlled the reported morphological and physiological criteria of
β-cells42.
Immunoﬂuorescent staining on grafts and/or pancreas. Insulin (Sigma-
Aldrich; #I2018, produced in mouse, 1:500 dilution), insulin (H-86, Santa Cruz,
#9168, produced in rabbit, 1:400 dilution), p-CREB (phospho-CREB-Ser133, Cell
Signaling; #9198, 1:500 dilution), CD31 (Abcam; #ab28364, 1:50 dilution), and
Ki67 (Ki67 [SP6], Thermo Fisher Scientiﬁc; #RM-9106, 1:250 dilution)
immunoﬂuorescence was performed on paraformaldehyde-ﬁxed, parafﬁn-
embedded grafts, or pancreatic sections, as described previously43. Brieﬂy, grafts or
whole pancreas, ﬁxed in 4% PBS-buffered paraformaldehyde overnight at 4 °C
before being processed and embedded in parafﬁn. Sections were cut at 5 μm for
pancreas and kidney grafts, deparafﬁnized, rehydrated, and incubated with a Target
Retrieval Solution (pH= 6, DAKO Corp, Carpinteria, CA, USA) in a pressure
cooker. Slides were then washed in distilled water and incubated with 5% goat
serum in PBS containing 1% BSA for 1 h at room temperature. Subsequently
sections were incubated overnight at 4 °C in hydration chambers with the
respective primary antibody (1 h at room temperature for CD31). Slides were then
washed in PBS and incubated with the respective secondary antibody for 1 h at
room temperature. The slides were washed in PBS and cover slipped with ProLong
Gold Antifade mounting medium (Thermo Fisher Scientiﬁc Inc. Waltham, MA,
USA). Sections were imaged via a Leica SP8 confocal microscope. Entire sections of
the pancreas were scanned and imaged using the Leica LAS Power Mosaic (Leica
Microsystems, Wetzlar, Germany). For quantiﬁcation of Ki67-positive cells in the
islet grafts from placebo or BIBO3304-treated mice, six sections separated by at
least 150 μm were used for each mouse, n= 3 mice per group. Investigators were
blinded to outcome assessment.
Western blotting. Isolated mouse islets were mechanically homogenized in ice
cold RIPA lysis buffer (50 mM Hepes [pH 7.4], 1% (v/v) Triton X-100, 1% (v/v)
sodium deoxycholate, 0.1% (v/v) SDS, 150 mM NaCl, 10% (v/v) glycerol, 1.5 mM
MgCl2, 1 mM EGTA, 50 mM NaF, 2 mM phenylmethysulfonyl ﬂuoride, 1 mM
sodium vanadate), and clariﬁed by centrifugation (100,000×g for 5 min at 4 °C).
Cell lysates were resolved by SDS–PAGE and immunoblotted with phospho-
speciﬁc CREB antibody (phospho-CREB-Ser133, Cell Signaling; #9198, 1:1000
dilution) or alpha-tubulin monoclonal antibody (clone B-5-1-2, #T6074,
Sigma-Aldrich, 1:1000 dilution) as a loading control.
Islet transplantation. To induce diabetes, 8–10-week-old recipient C57BL/6Ausb
mice were i.v. injected with alloxan tetrahydrate (Sigma-Aldrich) in injectable
grade water (20 mg/ml) at a dose of 110 mg/kg body weight. Mice with blood
glucose values ≥18 mmol/l were selected as transplant recipients. Islets were
isolated from pancreas of either Y1−/−mice or control donor mice and transplanted
into the recipient diabetic mice (syngeneic) as previously described44. In brief, on
the transplant day, islets were prepared from the pancreata of donor mice and
either 300 or 60 handcounted islets were transplanted into individual recipient
mice. For the transplant, the kidney was accessed by a left ﬂank incision and
brought into the wound by gentle blunt dissection. A small nick was made in the
kidney capsule at the inferior renal pole and the islets were deposited through the
nick toward the superior pole of the kidney. Blood glucose levels were monitored
daily. Transplanted mice underwent different regimes as detailed in the text.
Nephrectomy was performed at a speciﬁc postoperative day as indicated in the text
or ﬁgures.
Treatment plan, monitoring and study endpoints in NOD mice. Seven-week-old
female NOD mice were fed with placebo jelly or 0.5 μM BIBO3304 containing jelly
daily. When a blood glucose level of > 12 mM was recorded in BIBO3304-treated
mice, these mice were given an increased dose (5 μM BIBO3304) to examine the
possibility of reverting the trend. In another experiment, female NOD mice were
treated daily with either 0.5 μM BIBO3304 containing jelly or vehicle jelly. Glucose
levels were monitored weekly prior to 12 weeks of age and twice per week after
12 weeks of age. In these mice a GTT was carried out at 4, 8, and 12 weeks post
treatment or daily post hyperglycemia. Animals were also monitored daily for signs
of deteriorating health, as indicated by weight loss, slow movement, hunched
posture, and polyuria. Mice deemed morbid by the above criteria were sacriﬁced.
Pancreas from 12-week-old or 22-week-old female NOD mice treated with
BIBO3304 or placebo were formalin ﬁxed, parafﬁn embedded, and stained with
H&E to evaluate islet insulitis. The histology of the pancreatic islets was evaluated
by using a bright ﬁeld microscopy. The insulitis was scored in four levels. The total
number of the islets in the preparations were taken into account together with the
inﬁltration of lymphocytes. Representations of the different insulitis scores were
shown as below: Grade 0= no insulitis, representing normal islet morphology;
Grade 1 = peri-islet insulitis, representing < 25% inﬁltration with inﬂammation
concentrated around the islet; Grade 2= intermediate insulitis, representing
25–50% of the islet was penetrated by inﬂammatory inﬁltrate; Grade 3= intra-islet
insulitis, representing 50–75% of the islet was penetrated by inﬂammatory
inﬁltrate; and Grade 4 = complete islet insulitis, representing > 75% of the islet was
penetrated by inﬂammatory inﬁltrate. The treatments were unknown to the scoring
person to ensure blind evaluation.
Human islet isolation, transplantation, and treatment plan. We obtained
approval for performing human islet studies from St Vincent’s Institute of Medical
Research and St. Vincent’s Clinical School Human Research Ethics Committee.
Consent for use of the islets for research was given by relatives of the donors.
Isolated human islets were prepared from two independent deceased donors and
puriﬁed using the modiﬁed method as previously described45, 46. Human islets
were cultured overnight and transplanted of 1400 cultured islet equivalents into
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alloxan-induced NOD RAG1−/− diabetic mice as described previously47. In brief,
the kidney was accessed by a left ﬂank small incision and brought into the wound
by gentle blunt dissection. A small nick was made in the kidney capsule at the
inferior renal pole. The islets were gently placed through the nick toward the
superior pole of the kidney. Subsequently, recipient mice were either orally
administered with placebo or Y1 receptor antagonist, BIBO3304 (0.5 μM) daily and
graft function was determined by monitoring fed blood glucose levels up to
18 days. Glucose tolerance tests (i.p. 1 g/kg body weight) were performed on day 7
post-transplantation. Nephrectomy was performed at postoperative day 18.
Flow cytometry. Cell suspensions of spleen and lymph nodes were prepared
according to standard protocols and stained for FACS analysis in PBS containing
0.5% BSA, 2 mM EDTA, and 0.02% sodium azide using the following Abs
(obtained from BD Pharmingen, unless otherwise stated): Paciﬁc-Blue-conjugated
anti-CD4, FITC-conjugated, or PerCP-Cy5.5-conjugated (eBioscience) anti-CD8,
PerCP-Cy5.5-conjugated anti-B220, allophycocyanin-conjugated anti-CD44,
FITC-conjugated, or PerCP-Cy5.5-conjugated (eBioscience) anti-CD62L, PE-
conjugated CD25 (PC61.5), H-2K(d) Mouse IGRP 206-214 VYLKTNVFL
AlexaFlour 647-Labeled Tetramer (NIH Tetramer Core Facility), I-A(g7) BDC2.5
mimotope AHHPIWARMDA PE-Labeled Tetramer (NIH Tetramer Core Facility).
Samples were acquired on a LSRII Sorp (BD Biosciences) and data were analyzed
with FlowJo software (Tree Star). Gating strategy: Following labelling events were
gated on PI-lymphocytes (to exclude dead cells) using forward and side light scatter
parameters, then gated for CD4+CD8−, or CD4−CD8+ events respectively. To
assess the frequency of tetramer-positive events gates were drawn by setting the
control tetramer gate to 0.1% and using this gate for the corresponding tetramer
stained sample. Data is the percentage of tetramer-positive events among all CD4+
or all CD8+ cells, respectively.
Statistical analyses. All data are expressed as mean± SEM. A two-tailed Student’s
t-test was used to test difference between two groups of mice. Differences among
groups of mice were assessed by two-way ANOVA or repeated-measures ANOVA.
Bonferroni post hoc tests were performed to identify differences among means.
F test was used to compare variances. Statistical analyses were assessed using Prism
software (GraphPad Software 6.0 f, Inc, LaJolla, CA, USA). Sample size was
predetermined based on the variability observed in prior experiments and on
preliminary data. All experiments requiring the use of animals or animals to derive
cells were subject to randomization based on litter. Investigators were not blinded
to outcome assessment except were otherwise stated. Differences were regarded as
statistically signiﬁcant if *P< 0.05; **P< 0.01; ***P< 0.001 ****P< 0.0001.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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